title: Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.
abstract: The natural history of cystic fibrosis lung disease is one of chronic progression with intermittent episodes of acute worsening of symptoms frequently called acute pulmonary exacerbations These exacerbations typically warrant medical intervention. It is important that appropriate therapies are recommended on the basis of available evidence of efficacy and safety. The Cystic Fibrosis Foundation therefore established a committee to define the key questions related to pulmonary exacerbations, review the clinical evidence using an evidence-based methodology, and provide recommendations to clinicians. It is hoped that these guidelines will be helpful to clinicians in the treatment of individuals with cystic fibrosis.
authors.affiliation: Department of Medicine and Pediatrics, Medical University of South Carolina, Charleston, South Carolina 29425, USA. flumepa@musc.edu
authors.forename: Patrick A
authors.initials: PA
authors.lastname: Flume
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Mogayzel
authors.forename: Karen A
authors.initials: KA
authors.lastname: Robinson
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Goss
authors.forename: Randall L
authors.initials: RL
authors.lastname: Rosenblatt
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Kuhn
authors.forename: Bruce C
authors.initials: BC
authors.lastname: Marshall
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000628:therapy*; D004357:Drug Synergism; D006801:Humans; D012138:Respiratory Therapy / Q000379:methods*; D047090:beta-Lactams / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D047090:beta-Lactams